Existing experiments have shown that SOX5 is highly expressed in many malignant tumors, including prostate cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and other malignant tumors (45–47). Here, SOX5 is linked to nasopharyngeal carcinoma.